Contract analysis

I. Executive Summary Calderwood & Harkness LLP ("C&H") has been retained by Genome Dx Therapeutics Inc. ("GenomeDx" or "GDT"), a clinical-stage biotechnology company headquartered at 450 Genome Way, Suite 300, South San Francisco, California 94080, to represent GenomeDx as borrower in connection with a proposed $15,000,000 senior secured bridge loan facility (the "Bridge Loan" or the "Facility"). This memorandum prov

II. Transaction Overview A. The Borrower — GenomeDx Background GenomeDx is a Delaware corporation, qualified to do business in the State of California. The company's Employer Identification Number is 82-4917263, and its Delaware file number is 7481263. GenomeDx's registered agent in Delaware is National Registered Agents of Delaware Inc., located at 1209 Orange Street, Wilmington, Delaware 19801. GenomeDx was founded

1. Pinnacle Venture Lending Corp. Pinnacle Venture Lending Corp. is a Delaware corporation with its principal office at 2200 Sand Hill Road, Suite 400, Menlo Park, California 94025. Pinnacle is a specialty venture lending platform focused on providing debt financing to life sciences and technology companies, with approximately $2.8 billion in assets under management. The lead contact at Pinnacle for this transaction

2. Cobalt Life Sciences Fund III, L.P. Cobalt Life Sciences Fund III, L.P. is a Delaware limited partnership whose general partner is Cobalt Capital Management III LLC. Cobalt's principal office is located at 600 Lexington Avenue, 22nd Floor, New York, New York 10022. Cobalt is a healthcare-focused credit fund with approximately $1.4 billion in assets under management. The key contact at Cobalt is Priya Anand, Partne

1. Execution and Delivery of Transaction Documents. GenomeDx shall have executed and delivered (or caused to be executed and delivered) all transaction documents, including the Bridge Loan Agreement, the Security Agreement, the IP Security Agreement, the Warrant Agreements (one for each Lender), and the Intercreditor Agreement among Pinnacle (as Administrative Agent), Ridgeline, GenomeDx, and PFS (acknowledging).

2. Officer's Certificate. GenomeDx shall have delivered an officer's certificate, executed by an authorized officer, attaching (i) resolutions of the board of directors authorizing the transaction, (ii) a certified copy of GenomeDx's certificate of incorporation (as amended), (iii) GenomeDx's bylaws (as amended), and (iv) an incumbency certificate identifying the officers authorized to execute the transaction documen

3. Good Standing Certificates. GenomeDx shall have delivered certificates of good standing (or equivalent) from the Delaware Secretary of State and the California Secretary of State, each dated within ten (10) days of the closing date.

4. Perfection Deliverables. All perfection deliverables shall have been completed or arranged for, including (i) filing of UCC-1 financing statements with the Delaware Secretary of State and the California Secretary of State, (ii) execution and delivery of DACAs with First Basin National Bank for accounts **7834 and **2091, and (iii) execution and recording of the short-form IP Security Agreement with the USPTO.

5. C&H Legal Opinion. C&H shall have delivered to the Lenders a legal opinion in customary form, covering matters including due authorization, execution, delivery, enforceability, no conflicts, and perfection of the security interest.

6. HFC Legal Opinion. HFC shall have delivered to the Lenders a legal opinion in customary form for the benefit of the Lenders (this is an internal deliverable of the Lenders and does not require GenomeDx's involvement, but GenomeDx's cooperation with HFC's due diligence may be required).

7. Insurance Certificates. GenomeDx shall have delivered certificates of insurance evidencing (i) directors and officers liability insurance maintained with Sentinel Specialty Insurance Co. with a policy limit of $10,000,000, and (ii) general commercial liability insurance maintained with Commonwealth Mutual Insurance Group with a policy limit of $5,000,000. The certificates must show that the policies are in full fo

8. FY2025 Audited Financial Statements. GenomeDx shall have delivered its audited financial statements for the fiscal year ended December 31, 2025, prepared in accordance with generally accepted accounting principles (GAAP) and audited by Clearview & Associates LLP. The audit opinion, which is expected to be issued on February 14, 2026, will include a going-concern qualification, the implications of which are discuss

9. Payment of Fees. GenomeDx shall have paid (i) the commitment fee of $150,000 (Pinnacle: $100,000; Cobalt: $50,000) and (ii) the administrative agent fee of $25,000 to Pinnacle.

10. Lien Search Results. The Lenders shall have received lien search results (UCC, federal tax lien, judgment, and intellectual property searches) confirming that there are no liens or encumbrances on GenomeDx's assets other than Permitted Liens (which will be defined in the Bridge Loan Agreement to include the existing Ridgeline security interest in specifically identified equipment). G. Warrant Coverage and Convers

1. Warrant Coverage As part of the consideration for the Bridge Loan, GenomeDx will issue common stock purchase warrants to each Lender with an aggregate value equal to 3.00% of each Lender's commitment amount. The warrant coverage is calculated as follows: • Pinnacle: 3.00% × $10,000,000 = $300,000 in warrant value. At the Series B price of $2.18 per share, this equates to 137,614 warrant shares ($300,000 ÷ $2.18).

2. Bridge-to-Series C Conversion Option In addition to the warrant coverage, the Bridge Loan includes a conversion feature. If the Series C closes on or prior to the Maturity Date (March 6, 2027), the Lenders may elect to convert all or any portion of the outstanding principal of the Bridge Loan, plus accrued and unpaid interest, into shares of Series C preferred stock at a price per share equal to 80% of the Series

III. Key Negotiation Points and Risk Analysis This section identifies and analyzes the principal negotiation points and risk issues arising from the proposed Bridge Loan structure. These issues should guide the engagement team's approach in preparing the first draft of the Bridge Loan Agreement and in anticipating the positions that HFC and the Lenders are likely to take in the negotiation process. A. Interest Rate —

1. Background. GenomeDx has $3,200,000 outstanding under an equipment financing facility (the "Ridgeline Facility") with Ridgeline Capital Partners LLC ("Ridgeline"), which matures in December 2027. Ridgeline holds a first-priority security interest in specifically identified equipment financed under the Ridgeline Facility and the related proceeds of that equipment. In addition, the Ridgeline Facility includes a nega

2. Proposed Structure The proposed intercreditor arrangement would take the form of an intercreditor agreement among Pinnacle (in its capacity as Administrative Agent for the bridge lenders), Ridgeline, and GenomeDx, with PFS acknowledging in its capacity as Collateral Agent. The agreement would establish a split-collateral priority framework, as follows: • "Ridgeline Priority Collateral" — the specifically identifie

3. Analysis of Key Issues The following issues are expected to be the primary points of negotiation in the intercreditor agreement: (i) Definition of "Ridgeline Priority Collateral." The definition of Ridgeline Priority Collateral must be narrowly tailored to the specific equipment schedule under the existing Ridgeline Facility. We should resist any attempt by Ridgeline or Whitfield & Pratt to include after-acquired

1. Structure. If the Series C closes on or prior to March 6, 2027 (the Maturity Date), the Lenders may elect to convert all or any portion of the outstanding principal of the Bridge Loan, plus accrued and unpaid interest, into shares of Series C preferred stock at a price per share equal to 80% of the Series C price per share (i.e., at a 20% discount to the price paid by the Series C investors).

2. Scenario Analysis To assess the dilutive impact of the conversion option, we have prepared the following illustrative analysis based on the following assumptions: • Full $15,000,000 principal outstanding at the time of conversion. • Interest accrues for approximately six (6) months, assuming the Series C closes in August 2026, resulting in approximately $450,000 in accrued interest. • Total convertible amount: app

3. Impact on Existing Shareholders and Board Considerations Verdana currently holds approximately 24.6% of GenomeDx's fully diluted equity. If Verdana co-leads the Series C, its percentage ownership may be maintained or increased through its new investment, but the conversion discount creates "cheap shares" for the bridge lenders relative to the price paid by new Series C investors. This effectively reduces the per-s

4. Recommendation. GenomeDx should consider negotiating a cap on the convertible amount — for example, limiting the conversion to outstanding principal only, excluding accrued interest — to reduce the dilutive impact. Alternatively, GenomeDx could propose a higher discount floor (e.g., a 15% discount rather than 20%) or a cap on the aggregate number of shares issuable upon conversion. However, the conversion option i

1. Overview. As described in Section II.G, the Lenders will receive common stock purchase warrants with a total value equal to 3.00% of each Lender's commitment amount, resulting in the issuance of 206,421 warrant shares in the aggregate (Pinnacle: 137,614 shares; Cobalt: 68,807 shares). The exercise price of the warrants is the lesser of (a) $2.18 per share (the Series B price) and (b) 80% of the per-share price in

2. Dilutive Impact The 206,421 warrant shares represent approximately 0.43% incremental dilution relative to GenomeDx's existing fully diluted capitalization of approximately 48,500,000 shares (calculated as 206,421 ÷ 48,500,000). This level of dilution is modest and falls within market norms for venture bridge transactions, where warrant coverage of 2% to 5% of commitment amounts is typical, generally resulting in 0

3. Exercise Price Ratchet The warrant exercise price includes a ratchet feature: the exercise price is the lesser of the Series B price ($2.18) or 80% of the Series C price per share. This means that if the Series C is priced above $2.73 per share ($2.18 ÷ 0.80 = $2.725), the exercise price will default to $2.18, the Series B price. Given the indicative Series C pre-money valuation of $140,000,000, the expected Serie

4. Anti-Dilution and Transfer Provisions The Warrant Agreements will include anti-dilution protections for the Lenders. From GenomeDx's perspective, broad-based weighted-average anti-dilution is strongly preferred over full-ratchet anti-dilution. A full-ratchet provision would reprice the warrants to the lowest price at which GenomeDx issues equity in a subsequent "down round," regardless of the size of the down-roun

1. Covenant Structure The minimum cash covenant requires GenomeDx to maintain unrestricted cash and cash equivalents of not less than $3,000,000 at all times, tested monthly as of the last business day of each calendar month. A breach of this covenant would constitute an Event of Default under the Bridge Loan Agreement, potentially entitling the Lenders to accelerate the outstanding obligations and exercise remedies

2. Cash Runway Analysis GenomeDx's cash runway is currently estimated to extend through Q2 2026 absent new capital. With the $15,000,000 in Bridge Loan proceeds, less estimated closing costs of approximately $350,000 to $375,000 (consisting of the $150,000 commitment fee, the $25,000 administrative agent fee, and estimated Lenders' counsel and Borrower's counsel fees), net funding to GenomeDx is approximately $14,625

3. Covenant Compliance Risk The $3,000,000 minimum cash covenant creates an effective "cushion" that reduces the amount of bridge proceeds available for operations. If GenomeDx's total cash position (existing cash plus net bridge proceeds) is approximately $16,000,000 — a reasonable estimate pending confirmation — and the monthly burn rate is $3,000,000, the company would breach the $3,000,000 minimum cash covenant i

4. Recommendation. We recommend the following actions with respect to the minimum cash covenant: (i) Obtain detailed cash projections. As a first priority, we should obtain detailed twelve-month cash flow projections from Rob Langford to model covenant compliance under various scenarios, including (a) a base case in which the Series C closes in August 2026 as targeted, (b) a delay scenario in which the Series C close

1. Background. Clearview & Associates LLP (Sandra Cho, Audit Partner) is expected to issue the FY2025 audit opinion on February 14, 2026. Based on our preliminary discussions with Rob Langford and Miriam Sato, the audit opinion will be unqualified but will include a going-concern qualification (technically, an "emphasis-of-matter" paragraph regarding going concern), contingent on GenomeDx's ability to obtain addition

2. Significance for the Transaction A going-concern note signals to creditors, investors, and counterparties that the auditors have identified conditions that raise substantial doubt about GenomeDx's ability to continue as a going concern. While a going-concern qualification is a common feature for clinical-stage biotechnology companies that have not yet achieved profitability and are dependent on external financing,

3. Recommendation. Ensure that the MAC representation in the Bridge Loan Agreement includes a specific carve-out for the going-concern qualification in the FY2025 audit opinion. Flag this matter for the team members drafting the disclosure schedules, so that the going-concern note is properly disclosed. Coordinate with Miriam Sato on messaging to Argonaut and other potential Series C investors. G. Mandatory Prepaymen

1. Mandatory Prepayment Trigger The Bridge Loan Agreement will require GenomeDx to apply 100% of the net cash proceeds from any equity financing raising gross proceeds in excess of $20,000,000 to the repayment of the Bridge Loan in full, including all outstanding principal, accrued and unpaid interest, and any other amounts owing under the Facility. The anticipated Series C targets $60,000,000 to $75,000,000 in gross

2. Interplay with Conversion Option The mandatory prepayment obligation and the Lenders' conversion option must be carefully coordinated in the Bridge Loan Agreement to ensure a clear and workable framework. Specifically, the following issues must be addressed: (i) Conversion Election Deadline. The Lenders' deadline for electing to convert their Bridge Loan claims into Series C preferred stock must be set prior to, o

3. Timing Considerations The Series C is targeted for Q3 2026, with a closing expected in August or September 2026. If the Series C closes at that time, the Bridge Loan will have been outstanding for approximately five to six months, with approximately $375,000 to $450,000 in accrued interest. The total repayment or conversion amount would be approximately $15,375,000 to $15,450,000.

4. Risk — Series C Does Not Close If the Series C does not close before March 6, 2027 (the Maturity Date), the full $15,000,000 in principal plus approximately $900,000 in accrued interest (assuming twelve months of accrual at 6.00% per annum) will be due and payable in cash at maturity. Given GenomeDx's current cash position and projected burn rate, the company will almost certainly not have the liquidity to repay t

5. Drafting Considerations $20,000,000 Threshold. We should ensure that the $20,000,000 gross proceeds threshold for mandatory prepayment is tested on a per-transaction basis, not on a cumulative or aggregate basis. If the threshold were applied on a cumulative basis, a series of smaller equity raises — such as an insider round to cure a cash shortfall or a small strategic investment — could be aggregated to exceed $

6. Verdana Comfort Letter Verdana has delivered a comfort letter (not a guarantee) to the Lenders expressing its intent to participate in the Series C. This comfort letter is not legally binding and does not create an enforceable obligation on the part of Verdana to invest in the Series C or to invest at any particular valuation or on any particular terms. However, the comfort letter provides some degree of comfort r

7. Recommendation. (i) Clarify the conversion election mechanics and timing in the Bridge Loan Agreement, ensuring that the conversion election deadline precedes the mandatory prepayment trigger date. (ii) Confirm that the $20,000,000 gross proceeds threshold is tested on a per-transaction basis, not on a cumulative basis. (iii) Consider whether GenomeDx needs a carve-out for equity raises below $20,000,000 that are

IV. Additional Structural and Process Considerations A. Deposit Account Control Agreements DACAs are required at First Basin National Bank for GenomeDx's operating account (account number ending in **7834) and payroll account (account number ending in **2091). DACAs are necessary to perfect the Lenders' security interest in GenomeDx's deposit accounts under UCC § 9-104. Based on our experience with similar transactio